scholarly journals Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators

2021 ◽  
Author(s):  
Gisele Nishiguchi ◽  
Fatemeh Keramatnia ◽  
Jaeki Min ◽  
Yunchao Chang ◽  
Barbara Jonchere ◽  
...  
Keyword(s):  
Small Molecule ◽  
Orally Bioavailable

Discovery of Potent, Orally Bioavailable Small-Molecule Inhibitors of the Human CCR2 Receptor

ChemMedChem ◽  
2008 ◽  
Vol 3 (4) ◽  
pp. 660-669 ◽  
Author(s):  
Julien Doyon ◽  
Erwin Coesemans ◽  
Staf Boeckx ◽  
Mieke Buntinx ◽  
Bart Hermans ◽  
...  
Keyword(s):  
Small Molecule ◽  
Small Molecule Inhibitors ◽  
Orally Bioavailable

SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo

2014 ◽  
Vol 351 (1) ◽  
pp. 143-150 ◽  
Author(s):  
Lu Wang ◽  
Jing Ai ◽  
Yanyan Shen ◽  
Haotian Zhang ◽  
Xia Peng ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Small Molecule ◽  
Met Inhibitor ◽  
Orally Bioavailable

scholarly journals Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen

2015 ◽  
Vol 58 (4) ◽  
pp. 1717-1735 ◽  
Author(s):  
Aurélie Mallinger ◽  
Simon Crumpler ◽  
Mark Pichowicz ◽  
Dennis Waalboer ◽  
Mark Stubbs ◽  
...  
Keyword(s):  
Wnt Signaling ◽  
Small Molecule ◽  
Small Molecule Inhibitors ◽  
A Cell ◽  
Orally Bioavailable

scholarly journals Idelalisib in the management of lymphoma

Blood ◽  
2016 ◽  
Vol 128 (3) ◽  
pp. 331-336 ◽  
Author(s):  
Chan Yoon Cheah ◽  
Nathan H. Fowler
Keyword(s):  
Clinical Experience ◽  
Small Molecule ◽  
Therapeutic Strategy ◽  
Pi3k Pathway ◽  
Phosphatidylinositol 3 Kinase ◽  
Mechanisms Of Resistance ◽  
Preclinical Data ◽  
Combination Strategies ◽  
Orally Bioavailable ◽  
Phosphatidylinositol 3

Abstract Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies.

scholarly journals Potent, Orally Bioavailable Diazabicyclic Small-Molecule Mimetics of Second Mitochondria-Derived Activator of Caspases

2008 ◽  
Vol 51 (24) ◽  
pp. 8158-8162 ◽  
Author(s):  
Yuefeng Peng ◽  
Haiying Sun ◽  
Zaneta Nikolovska-Coleska ◽  
Su Qiu ◽  
Chao-Yie Yang ◽  
...  
Keyword(s):  
Small Molecule ◽  
Orally Bioavailable

ChemInform Abstract: Amidinohydrazones as Guanidine Bioisosteres: Application to a New Class of Potent, Selective and Orally Bioavailable, Non-amide-based Small-Molecule Thrombin Inhibitors.

ChemInform ◽  
2010 ◽  
Vol 31 (18) ◽  
pp. no-no
Author(s):  
Richard M. Soll ◽  
Tianobao Lu ◽  
Bruce Tomczuk ◽  
Carl R. Illig ◽  
Cynthia Fedde ◽  
...  
Keyword(s):  
Small Molecule ◽  
Thrombin Inhibitors ◽  
New Class ◽  
Orally Bioavailable
Sign in / Sign up

Export Citation Format

Share Document